Literature DB >> 22625413

Reversible Michael additions: covalent inhibitors and prodrugs.

Martin H Johansson1.   

Abstract

Covalent inhibition is an efficient molecular mechanism for inhibiting enzymes or modulating the function of proteins and is found in the action of many drugs and biologically active natural products. However, it is has been less appreciated that the formation of covalent bonds can be reversible or irreversible. This review focuses on biologically active compounds that are Michael acceptors and how the reversible nature of the Michael addition reaction influences biological activity and how this can be exploited in designing prodrugs.

Mesh:

Substances:

Year:  2012        PMID: 22625413     DOI: 10.2174/13895575112091330

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  27 in total

Review 1.  Covalent targeting of acquired cysteines in cancer.

Authors:  Marieke Visscher; Michelle R Arkin; Tobias B Dansen
Journal:  Curr Opin Chem Biol       Date:  2015-11-28       Impact factor: 8.822

2.  Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.

Authors:  John R Horton; Clayton B Woodcock; Qin Chen; Xu Liu; Xing Zhang; John Shanks; Ganesha Rai; Bryan T Mott; Daniel J Jansen; Stephen C Kales; Mark J Henderson; Matthew Cyr; Katherine Pohida; Xin Hu; Pranav Shah; Xin Xu; Ajit Jadhav; David J Maloney; Matthew D Hall; Anton Simeonov; Haian Fu; Paula M Vertino; Xiaodong Cheng
Journal:  J Med Chem       Date:  2018-11-15       Impact factor: 7.446

Review 3.  Recent advances in C-heteroatom bond forming by asymmetric Michael addition.

Authors:  Majid M Heravi; Parvin Hajiabbasi
Journal:  Mol Divers       Date:  2013-12-31       Impact factor: 2.943

4.  Design and synthesis of novel antimicrobials with activity against Gram-positive bacteria and mycobacterial species, including M. tuberculosis.

Authors:  V V N Phani Babu Tiruveedhula; Christopher M Witzigmann; Ranjit Verma; M Shahjahan Kabir; Marc Rott; William R Schwan; Sara Medina-Bielski; Michelle Lane; William Close; Rebecca L Polanowski; David Sherman; Aaron Monte; Jeffrey R Deschamps; James M Cook
Journal:  Bioorg Med Chem       Date:  2013-10-21       Impact factor: 3.641

Review 5.  Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors.

Authors:  Letitia Shunmugam; Pritika Ramharack; Mahmoud E S Soliman
Journal:  Protein J       Date:  2017-10       Impact factor: 2.371

6.  Monocarbonyl analogs of curcumin inhibit growth of antibiotic sensitive and resistant strains of Mycobacterium tuberculosis.

Authors:  Patrick R Baldwin; Analise Z Reeves; Kimberly R Powell; Ruth J Napier; Alyson I Swimm; Aiming Sun; Kyle Giesler; Bettina Bommarius; Thomas M Shinnick; James P Snyder; Dennis C Liotta; Daniel Kalman
Journal:  Eur J Med Chem       Date:  2015-01-10       Impact factor: 6.514

7.  Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells.

Authors:  Julian Laux; Michael Forster; Laura Riexinger; Anna Schwamborn; Jamil Guezguez; Christina Pokoj; Mark Kudolo; Lena M Berger; Stefan Knapp; Dieter Schollmeyer; Jan Guse; Michael Burnet; Stefan A Laufer
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-14

8.  Structural characterization of dicyanopyridine containing DNMT1-selective, non-nucleoside inhibitors.

Authors:  John R Horton; Sarath Pathuri; Kristen Wong; Ren Ren; Lourdes Rueda; David T Fosbenner; Dirk A Heerding; Michael T McCabe; Melissa B Pappalardi; Xing Zhang; Bryan W King; Xiaodong Cheng
Journal:  Structure       Date:  2022-04-07       Impact factor: 5.871

9.  Metabolism and disposition of pyrotinib in healthy male volunteers: covalent binding with human plasma protein.

Authors:  Jian Meng; Xiao-Yun Liu; Sheng Ma; Hua Zhang; Song-da Yu; Yi-Fan Zhang; Mei-Xia Chen; Xiao-Yu Zhu; Yi Liu; Ling Yi; Xiao-Liang Ding; Xiao-Yan Chen; Li-Yan Miao; Da-Fang Zhong
Journal:  Acta Pharmacol Sin       Date:  2018-10-31       Impact factor: 6.150

10.  Nrf2 and HSF-1 Pathway Activation via Hydroquinone-Based Proelectrophilic Small Molecules is Regulated by Electrochemical Oxidation Potential.

Authors:  Takumi Satoh; Romain Stalder; Scott R McKercher; Robert E Williamson; Gregory P Roth; Stuart A Lipton
Journal:  ASN Neuro       Date:  2015-08-03       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.